Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Anixa Biosciences, Inc.

ANIX

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Last trade $2.67
Day change +$0.12 (+4.71%)
Day range $2.55 – $2.70
Volume 159,909
Market cap $89M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$88.65M
Price / earnings
—
Price / book
6.13×
Price / sales
—
EV / sales
—
EV / EBITDA
-7.95×

Profitability

Earnings per share
-$0.30
Return on assets
-68.87%
Return on equity
-71.74%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
8.54×
Quick ratio
8.54×
Cash ratio
0.8×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$7.38M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ANIX, quarterly periods
Line itemQ3 FY2026 Jul 31, 2026Q2 FY2026 Apr 30, 2026Q1 FY2026 Jan 31, 2026Q4 FY2025 Oct 31, 2025Q3 FY2025 Jul 31, 2025Q2 FY2025 Apr 30, 2025Q1 FY2025 Jan 31, 2025Q4 FY2024 Oct 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$1.41M$1.39M$1.61M$1.73M$1.38M$1.68M$1.83M$1.69M
Research and development$1.33M$1.26M$1.1M$1.14M$1.06M$1.32M$1.55M$1.48M
Total operating expenses$2.74M$2.65M$2.72M$2.88M$2.44M$3M$3.39M$3.16M
Operating income-$2.74M-$2.65M-$2.72M-$2.88M-$2.44M-$3M-$3.39M-$3.16M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$2.63M-$2.54M-$2.59M-$2.72M-$2.28M-$2.81M-$3.21M-$2.91M
Income taxes$0$0$0$0$0$0$0$0
Net income-$2.63M-$2.54M-$2.59M-$2.72M-$2.28M-$2.81M-$3.21M-$2.91M
Net income attributable to common shareholders-$2.61M-$2.52M-$2.57M-$2.7M-$2.26M-$2.79M-$3.18M-$2.88M
EBITDA-$2.74M-$2.65M-$2.72M-$2.88M-$2.44M-$3M-$3.39M-$3.16M
Basic earnings per share-$0.08-$0.07-$0.08-$0.08-$0.07-$0.09-$0.10-$0.09
Diluted earnings per share-$0.08-$0.07-$0.08-$0.08-$0.07-$0.09-$0.10-$0.09

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology

Anixa Biosciences announced that the Mexican Institute of Industrial Property has issued Patent Number 432748 covering the company's breast cancer vaccine technology. The patent extends intellectual property protection into 2040 and strengthens Anixa's global patent portfolio. The vaccine, developed with Cleveland Clinic, targets human α-lactalbumin and showed positive Phase 1 results with 74% of participants eliciting protocol-defined immune responses. The company is preparing for Phase 2 clinical trials.

Benzinga

Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology

Anixa Biosciences announced that South Korea's Ministry of Intellectual Property issued a Notice of Allowance for a patent covering the company's breast cancer vaccine technology. The patent, exclusively licensed from Cleveland Clinic, provides composition of matter protection in South Korea and expands Anixa's global intellectual property portfolio. The company's Phase 1 clinical trial showed the vaccine was safe, well-tolerated, and generated immune responses in 74% of participants.

Benzinga

Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals

The cancer immunotherapy market is projected to reach $258.22 billion by 2031, driven by breakthrough treatments and FDA fast-track approvals. Multiple companies are developing innovative immunotherapies targeting various cancer types with promising clinical trial results.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.